Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

Martin Dreyling, MD, Marco Ladetto, MD, Jeanette K. Doorduijn, MD PhD, Eva Gine, MD, Mats Jerkeman, MD Professor, Ulrich Mey, MD, Michal Szymczyk, MD, Martin Hutchings, MD PhD, Arne Kolstad, MD PhD, Gregor Verhoef, MD PhD, Marek Trneny, MD prof, Maria Gomes da Silva, MD, Christiane Pott, MD PhD, Wolfram Klapper, Michael Unterhalt, PhD, Eva Hoster, PhD

Blood (2019) 134 (Supplement_1): 2816.

https://doi.org/10.1182/blood-2019-127863

Published: 2019

Journal Articles

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma

Anne Shah, MS, Allison Petrilla, MPH, Mayvis Rebeira, PhD, Joseph Feliciano, PharmD, Thomas W. LeBlanc, MDMA,MHS, Julie Lisano, PharmD

Blood (2019) 134 (Supplement_1): 3492.

https://doi.org/10.1182/blood-2019-130973

Published: 2019

Journal Articles

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

Jessica J Jalbert, PhD, Umesh Chaudhari, MD, Haixin Zhang, MSc, Jonathan Weyne, MD, Jamile M. Shammo, MD

Blood (2019) 134 (Supplement_1): 3407.

https://doi.org/10.1182/blood-2019-125867

Published: 2019

Journal Articles

FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy

Anja Mottok, Vindi Jurinovic, Pedro Farinha, Andreas Rosenwald, Ellen Leich, German Ott, Heike Horn, Wolfram Klapper, Michael Boesl, Wolfgang Hiddemann, Christian Steidl, Joseph M. Connors, Laurie H. Sehn, Randy D. Gascoyne, Eva Hoster, Oliver Weigert, Robert Kridel

Blood (2018) 131 (2): 226–235.

https://doi.org/10.1182/blood-2017-08-799080

Published: 2018

Includes: Supplemental data

Journal Articles

Real Life Data on Clinical Aspects and Treatment of Marginal Zone Lymphoma: An Analysis from the NF10 Project, an International, Prospective, Observational Study of the Fondazione Italiana Linfomi

Blood (2017) 130 (Supplement 1): 1493.

https://doi.org/10.1182/blood.V130.Suppl_1.1493.1493

Published: 2017

Journal Articles

Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease

Jeanne Palmer, Xiaoyu Chai, Joseph Pidala, Yoshihiro Inamoto, Paul J. Martin, Barry Storer, Iskra Pusic, Mary E. D. Flowers, Mukta Arora, Steven Z. Pavletic, Stephanie J. Lee

Blood (2016) 127 (1): 160–166.

https://doi.org/10.1182/blood-2015-08-662874

Published: 2016

Includes: Supplemental data

Journal Articles

Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis

Blood (2015) 126 (23): 2636.

https://doi.org/10.1182/blood.V126.23.2636.2636

Published: 2015

Journal Articles

Late Relapse in Hodgkin Lymphoma (HL): A Retrospective Analysis of Patients Enrolled on Clinical Trials at the Istituto Nazionale Tumori of Milan (INT-MI)

Simonetta Viviani, MD, Alberto Mussetti, MD, Oreste Di Bartolo, MD, Antonello Cabras, MD, Pinuccia Valagussa, Statistician, Gianni Bonadonna, MD, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2015) 126 (23): 2697.

https://doi.org/10.1182/blood.V126.23.2697.2697

Published: 2015

Journal Articles

FFS: an end(point) to our problems in chronic GVHD trials?

David A. Jacobsohn

Blood (2014) 124 (8): 1216–1217.

https://doi.org/10.1182/blood-2014-06-579672

Published: 2014

Journal Articles

Medicare Fee-for-Service Enrollees with Acute Myelogenous Leukemia: An Analysis of Treatment Patterns and Patient Survival

Juliana Leah Meyers, MA, Yanni F Yu, Keith L Davis

Blood (2011) 118 (21): 505.

https://doi.org/10.1182/blood.V118.21.505.505

Published: 2011

Journal Articles

Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.

Annalisa Chiappella, Benedetta Puccini, Marianna Rossi, Simone Ferrero, Luca Arcaini, Ernesta Audisio, Ileana Baldi, Carola Boccomini, Barbara Botto, Fabbri Alberto, Chiara Frairia, Roberto Freilone, Marco Ladetto, Domenico Novero, Marco Paulli, Patrizia Pregno, Giorgio Priolo, Luigi Rigacci, Umberto Vitolo

Blood (2009) 114 (22): 2928.

https://doi.org/10.1182/blood.V114.22.2928.2928

Published: 2009

Journal Articles

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Jorge Enrique Romaguera, MD, Luis Fayad, M.D., Maria Alma Rodriguez, M.D., F.B. Hagemeister, M.D., Barbara Pro, M.D., Peter McLaughlin, M.D., Anas Younes, M.D., Felipe Samaniego, M.D., Andre Goy, M.D., Andreas H. Sarris, M.D., Nam H. Dang, M.D., Luhua Wang, M.D., Hagop M. Kantarjian, M.D., Virginia Beasley, L. Jeffrey Medeiros, M.D., Ruth L. Katz, M.D., Fernando Cabanillas, M.D.

Blood (2006) 108 (11): 2749.

https://doi.org/10.1182/blood.V108.11.2749.2749

Published: 2006

Journal Articles

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

Jorge Enrique Romaguera, MD, Luis Fayad, MD, Maria A. Rodriguez, MD, Fredrick B. Hagemeister, MD, Barbara Pro, MD, Peter McLaughlin, MD, Anas Younes, MD, Felipe Samaniego, MD, Andre Goy, MD, Andreas H. Sarris, MD, Ph.D., Nam H. Dang, MD, Ph.D., L. Jeffrey Medeiros, MD, Ruth Katz, MD, Harish Gagneja, MD, Barry I. Samuels, MD, Fernando Cabanillas, MD

Blood (2004) 104 (11): 128.

https://doi.org/10.1182/blood.V104.11.128.128

Published: 2004

Journal Articles

BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens

George Z. Rassidakis, L. Jeffrey Medeiros, Theodoros P. Vassilakopoulos, Simonetta Viviani, Valeria Bonfante, Gianpaolo Nadali, Marco Herling, Maria K. Angelopoulou, Roberto Giardini, Marco Chilosi, Christos Kittas, Timothy J. McDonnell, Gianni Bonadonna, Alessandro M. Gianni, Giovanni Pizzolo, Gerassimos A. Pangalis, Fernando Cabanillas, Andreas H. Sarris

Blood (2002) 100 (12): 3935–3941.

https://doi.org/10.1182/blood.V100.12.3935

Published: 2002

Journal Articles

Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients

Jose I. Chacón, Manuela Mollejo, Enriqueta Muñoz, Patricia Algara, Marisol Mateo, Luis Lopez, Jesús Andrade, Iciar Garcı́a Carbonero, Beatriz Martı́nez, Miguel A. Piris, Miguel A. Cruz

Blood (2002) 100 (5): 1648–1654.

https://doi.org/10.1182/blood.V100.5.1648.h81702001648_1648_1654

Published: 2002

Journal Articles

Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)

Joseph A. Sparano, Edie Weller, Tipu Nazeer, Thomas Habermann, Ann E. Traynor, Jane Manalo, Peter Cassileth

Blood (2002) 100 (5): 1634–1640.

https://doi.org/10.1182/blood.V100.5.1634.h81702001634_1634_1640

Published: 2002

Journal Articles

Follicular Large Cell Lymphoma: An Aggressive Lymphoma That Often Presents With Favorable Prognostic Features

J. Rodriguez, P. McLaughlin, F.B. Hagemeister, L. Fayad, M.A. Rodriguez, M. Santiago, M. Hess, J. Romaguera, F. Cabanillas

Blood (1999) 93 (7): 2202–2207.

https://doi.org/10.1182/blood.V93.7.2202

Published: 1999

NARROW

Triangle: Autologous T ransplantation after a R ituximab/ I brutinib/ a ra-c Containing I n duction in G eneralized Mantle Cell L ymphoma - a Randomized E uropean MCL Network Trial

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy

Real Life Data on Clinical Aspects and Treatment of Marginal Zone Lymphoma: An Analysis from the NF10 Project, an International, Prospective, Observational Study of the Fondazione Italiana Linfomi

Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease

Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis

Late Relapse in Hodgkin Lymphoma (HL): A Retrospective Analysis of Patients Enrolled on Clinical Trials at the Istituto Nazionale Tumori of Milan (INT-MI)

FFS: an end(point) to our problems in chronic GVHD trials?

Medicare Fee-for-Service Enrollees with Acute Myelogenous Leukemia: An Analysis of Treatment Patterns and Patient Survival

Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens

Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients

Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)

Follicular Large Cell Lymphoma: An Aggressive Lymphoma That Often Presents With Favorable Prognostic Features

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only